Tedros Adhanom Ghebreyesus declared the Bundibugyo ebolavirus outbreak in DR Congo and Uganda a Public Health Emergency of International Concern on Sunday 17 May 20261. The WHO Director-General did not convene the IHR Emergency Committee, the body that under the 2005 International Health Regulations drafts the Temporary Recommendations a PHEIC is meant to deliver. The WHO statement records 8 lab-confirmed cases, 246 suspected and 80 suspected deaths across the Bunia, Rwampara and Mongbwalu health zones of Ituri Province, plus two confirmed Kampala cases and one in Kinshasa. The declaration explicitly states the outbreak does not meet the new Pandemic Emergency tier criteria introduced by the 2024 IHR amendments.
The Emergency Committee will be convened "as soon as possible", per the WHO statement. Maria Van Kerkhove, WHO's Director of Epidemic and Pandemic Preparedness, said the agency stood ready to deploy vaccines "should it turn out to be a strain where a vaccine can be used"2. Bundibugyo falls outside that conditional: no licensed vaccine or monoclonal therapy targets this Ebola species. Prior PHEIC declarations for COVID, mpox and polio had Emergency Committees seated before or alongside the declaration; the body that would ordinarily write travel, screening and trade guidance is being constituted after the headline rather than with it.
WHO's institutional memory of West Africa 2014-16 is doing visible work here. That outbreak was declared a PHEIC 4.5 months after the index case and ran to 28,000 cases and 11,000 deaths before vaccines and monoclonals reached patients. Tedros has chosen the opposite failure mode: sound the alarm now, write the operational sheet later. The WHO R&D Blueprint had pre-warned of the non-Zaire countermeasures gap in Q1 2026, three months before this outbreak surfaced; the ECDC had earlier flagged the same posture concerns about European preparedness for filovirus spillover. Both anticipated a moment exactly like this one, and the early signal is the corrective.
States parties opening contingency plans on Monday 18 May will not find a WHO-issued Temporary Recommendation telling them how to screen arrivals from Bunia, Kampala or Kinshasa. Pharmaceutical companies weighing compassionate-use decisions on cross-reactive monoclonals do so without a WHO target product profile attached to the declaration. The PABS annex extension agreed at IGWG6 on 1 May means the multilateral vaccine-sharing architecture that would govern equitable distribution is itself still negotiating its terms. The PHEIC headline now exists; the apparatus that ordinarily converts it into national health-security policy does not.
